Pricing of Public Offerings, Agreements, and Stock Movements- Research Report on MiMedx Group, NPS Pharmaceuticals, VIVUS,

Pricing of Public Offerings, Agreements, and Stock Movements- Research Report
 on MiMedx Group, NPS Pharmaceuticals, VIVUS, Merrimack Pharmaceuticals, and
                                    GenVec

PR Newswire

NEW YORK, December 17, 2013

NEW YORK, December 17, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting MiMedx
Group, Inc. (NASDAQ: MDXG), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), VIVUS
Inc. (NASDAQ: VVUS), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), and
GenVec, Inc. (NASDAQ: GNVC). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

MiMedx Group, Inc. Research Report

On December 12, 2013, MiMedx Group, Inc. (MiMedx) announced the pricing of an
underwritten public offering of 5 million shares of its common stock at a
price to the public of $6.80 per share for gross proceeds of $34.0 million.
According to the Company, the net proceeds from the sale of the shares, after
deductions, will be approximately $31.6 million. Additionally, MiMedx informed
that it has granted the underwriters a 30-day option to purchase up to an
additional 750,000 shares of common stock tocover any over-allotments. MiMedx
stated that offering's proceeds will be used for general corporate purposes
including research, development and further commercialization of the Company's
products, obtaining regulatory approvals, funding of clinical trials, capital
expenditures, working capital and future acquisitions of complementary
businesses, technology or products. MiMedx also stated that the offering is
expected to close on or about December 17, 2013, subject to customary closing
conditions. The Full Research Report on MiMedx Group, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/2fcc_MDXG

NPS Pharmaceuticals, Inc. Research Report

On December 12, 2013, NPS Pharmaceuticals, Inc.'s (NPS Pharmaceuticals) stock
went up by 6.45%, closing the day at $24.10. For the past three trading days,
NPS Pharmaceuticals' stock went up by 0.88%, compared to the Dow Jones
Industrial Average which went down by 1.79% during the same three day trading
period. The Full Research Report on NPS Pharmaceuticals, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/441a_NPSP

VIVUS Inc. Research Report

On December 12, 2013, VIVUS Inc. (VIVUS) announced that it has entered into a
License and Commercialization Agreement with Sanofi for commercializing
avanafil on an exclusive basis in Africa, the Middle East, Turkey, and the
Commonwealth of Independent States (CIS) including Russia. VIVUS stated that
Sanofi will be responsible for obtaining regulatory approval in its
territories, and plans to market avanafil under the tradename SPEDRA™ or
STENDRA™. The Company stated that under the terms of the agreement,itis
eligible to receive up to $61 million in upfront payments, regulatory and
sales milestones, and escalating royalties based on net sales over the life of
the agreement. Commenting on the release, John L. Slebir, Vice President,
Business Development and General Counsel of VIVUS, stated, "We are pleased
with the alliance we have forged with our partners at Sanofi. This agreement
is another key accomplishment for VIVUS in the monetization of avanafil."The
Full Research Report on VIVUS Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/8ae9_VVUS

Merrimack Pharmaceuticals, Inc. Research Report

On December 12, 2013, Merrimack Pharmaceuticals, Inc.'s (Merrimack
Pharmaceuticals) stock went up by 12.10%, to close the day at $4.54. The
Company's stock went up by 1.57% over the past three trading days, compared to
the Dow Jones Industrial Average which went down by 1.79% during the same
trading period. The Full Research Report on Merrimack Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/8bb0_MACK

GenVec, Inc. Research Report

On December 12, 2013, GenVec, Inc.'s (GenVec) stock climbed up 31.03% to close
the day at $2.28. Over the past three trading days, the Company's stock went
up by 23.91%, compared to the Nasdaq Composite which went down by 1.73% during
the same trading period. The Full Research Report on GenVec, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/49ad_GNVC

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Contact: Joe Thomas, +1-310-496-8071 (North America)